Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9024724 | 0.90 | GAA (0.46) | GAASMN1; SMN2NPSR1MCL1KDM4E | |
| SCHEMBL645408 | 0.81 | ALDH1A1 (0.33) | NPSR1ALDH1A1TSHR | |
| SCHEMBL3803757 | 0.77 | NPSR1 (0.42) | SMN1; SMN2NPSR1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4948936 | 0.77 | PDK2 (0.30) | — | |
| SCHEMBL15434645 | 0.76 | NPSR1 (0.48) | GAASMN1; SMN2NPSR1MCL1KDM4E | |
| SCHEMBL9287278 | 0.74 | NPSR1 (0.51) | GAASMN1; SMN2NPSR1MCL1KDM4E | |
| SCHEMBL4763149 | 0.73 | KDM4E (0.38) | GAASMN1; SMN2NPSR1MCL1KDM4E | |
| SCHEMBL19160151 | 0.71 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7029592 | 0.71 | KDM4E (0.38) | GAASMN1; SMN2NPSR1MCL1KDM4E | |
| SCHEMBL4946622 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011152485-A1 | NOVEL 4,5-FUSED PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-12-08 | — | — | WO | disclosed |
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| EP-2043744-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1395591-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-04 | — | — | EP | disclosed |
| EP-1383747-B1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008008895-A1 | GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008887-A2 | GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| EP-1395591-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1383747-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6514982-B1 | Corticotropin releasing factor is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone, beta -endorphin, and other pro-opiomelanocortin-derived peptides from the pituitary | NEUROCRINE BIOSCIENCES, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100863-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001087885-A1 | CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GAA 185/4885SMN1; SMN2 4391/4885NPSR1 1492/4885 |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | GAA 2746/4885SMN1; SMN2 786/4885NPSR1 14/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | GAA 2746/4885SMN1; SMN2 786/4885NPSR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.